Unknown

Dataset Information

0

IDH1-R132 changes vary according to NPM1 and other mutations status in AML.

ABSTRACT:

SUBMITTER: Falini B 

PROVIDER: S-EPMC6484707 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
| S-EPMC6771683 | biostudies-literature
Unknown NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.
| S-EPMC12797279 | biostudies-literature
Unknown NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML.
| S-EPMC8304368 | biostudies-literature
Unknown Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
| S-EPMC6613636 | biostudies-literature
Unknown Current status and future perspectives in targeted therapy of NPM1-mutated AML.
| S-EPMC9522592 | biostudies-literature
Unknown Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.
| S-EPMC8807394 | biostudies-literature
Unknown Integrating holotomography and deep learning for rapid detection of NPM1 mutations in AML.
| S-EPMC11467337 | biostudies-literature
Unknown Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
| S-EPMC10027507 | biostudies-literature
Unknown TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia.
| S-EPMC7760270 | biostudies-literature
Unknown Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
| S-EPMC9037756 | biostudies-literature